TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

TRACON Pharmaceuticals reports positive interim data, focuses on growth strategies

TRACON Pharmaceuticals showcased promising interim data from the ENVASARC trial, reflecting positive efficacy of ENVA treatment and strategic advancements in product development.
While facing challenges such as financial losses and regulatory compliance, TRACON's focus on cost-saving measures and operational efficiency positions it for sustainable growth.
The company's strong cash position, commitment to advancing its pipeline, and opportunities for collaboration and portfolio expansion signal a promising outlook for future growth and innovation.
By leveraging its product development platform and upcoming trial data releases, TRACON aims to drive value creation, financial stability, and regulatory compliance in the competitive pharmaceutical landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development, shares in the cost and risk of clinical development, and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States.

SAN DIEGO, June 16, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States, today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Maxim Group Healthcare Virtual Conference on Tuesday, June 20, 2023 at 3:30 pm Eastern Time.

TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference

SAN DIEGO, June 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States, today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 8:30 am Eastern Time.

TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States, today announced the presentation of two posters at the upcoming American Society of Clinical Oncology (ASCO) 2023 annual meeting, being held June 2-6, 2023.

TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Edward White - H.C. Wainwright & Co., LLC Joel Beatty - Robert W.

TRACON Pharmaceuticals, Inc. (TCON) Q1 2023 Earnings Call Transcript

SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.

TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its first quarter 2023 financial and operating results after the close of U.S. financial markets on Wednesday, May 10, 2023. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023

TRACON Pharmaceuticals (NASDAQ: TCON ) stock is falling on Tuesday following an update on a legal battle with I-Mab  (NASDAQ: IMAB ). The bad news for TCON stock comes from a legal ruling favoring I-Mab.

Why Is TRACON Pharma (TCON) Stock Down 51% Today?

SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that the tribunal in the arbitration against I-Mab conducted under the Rules of Arbitration of the International Chamber of Commerce (ICC) rendered an award to TRACON in the aggregate amount of approximately $23.0 million.

TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab

Tracon (TCON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Tracon (TCON) Moves to Buy: Rationale Behind the Upgrade

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Soumit Roy - Jones Research Joel Beatty - Robert W. Baird & Co. Robert Hazlett - BTIG Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Fourth Quarter and Year Ended 2022 Earnings Conference Call.

TRACON Pharmaceuticals, Inc. (TCON) Q4 2022 Earnings Call Transcript

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2022. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2022 financial and operating results after the close of U.S. financial markets on Wednesday, March 8, 2023. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023

Checkpoint Therapeutics

OmniAb Inc

Performant Financial

ProQR Therapeutics

Analysts Say These Are Penny Stocks To Buy But Are They Worth The Risk? The post 5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts

Initial $3.5M Funding Maintains Cash Runway of Mid-2023 Initial $3.5M Funding Maintains Cash Runway of Mid-2023

TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023

TRACON Pharmaceuticals Inc (NASDAQ:TCON) revealed that its PD-L1 antibody envafolimab achieved positive results based on the double-digit Objective Response Rate (ORR) assessed by a blinded independent central review in its ongoing multicenter ENVASARC Phase 2 pivotal trial in patients with Undifferentiated Pleomorphic Sarcoma (UPS) or Myxofibrosarcoma (MFS) cancers. According to TRACON, the independent data monitoring committee (IDMC) for the ongoing ENVASARC Phase 2 pivotal trial recommended "continued accrual as planned in both cohorts: single agent envafolimab and envafolimab in combination with Yervoy (ipilimumab).

TRACON achieves positive results based on Double-Digit Objective Response Rate in each cohort from ENVASARC Phase 2 Pivotal Trial

Objective Response Rate (ORR) by Central Review Achieved in Each Cohort at Interim Efficacy Analysis that Exceeded the Futility Threshold

TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial

Today, we look back in on clinical stage developmental firm TRACON Pharmaceuticals for the first time since early 2021. The company's primary drug candidate Envafolimab could provide certain advantages over other approved PD-L1 inhibitors.

Revisiting Tracon Pharmaceuticals

TRACON Pharmaceuticals Inc (NASDAQ:TCON) said it has dosed the first patient in a Phase 1/2 trial evaluating the company's CTLA-4 antibody, YH001, in combination with its PD-L1 antibody envafolimab and with doxorubicin, in front line therapy of patients with malignant tumours. The Phase 1/2 trial will assess the safety and efficacy of the triplet combination of YH001, envafolimab and doxorubicin in the common sarcoma sub-types of leiomyosarcoma and dedifferentiated liposarcoma, according to TRACON.

TRACON Pharmaceuticals doses first patient in drug trial to treat malignant tumours

SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced dosing of the first patient in a Phase 1/2 trial evaluating the Company's CTLA-4 antibody, YH001, in combination with its PD-L1 antibody envafolimab and with doxorubicin in front line therapy in patients with sarcoma (NCT 05448820).

TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Joel Beatty - Robert W. Baird & Co. Edward White - H.C.

TRACON Pharmaceuticals, Inc. (TCON) Q3 2022 Earnings Call Transcript

TRACON Pharmaceuticals Inc announced that it has ended its third-quarter 2022 with cash and equivalents of $17.0 million as of September 30, 2022, which the company says is expected to fund its operations into mid-2023. The clinical stage biopharmaceutical company also noted that its net loss for the quarter narrowed to $6.4 million from $7.0 million a year earlier, as it reduced its general and administrative expenses for the period to $2.3 million, compared to $4.2 million in 3Q 2021.

TRACON Pharmaceuticals ends 3Q with $17M cash and equivalents to fund operations into mid-2023

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the third quarter ended September 30, 2022. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.

TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

TRACON Pharmaceuticals Inc has received a recommendation from the Independent Data Monitoring Committee that its ENVASARC Phase 2 pivotal trial can proceed as planned, the company announced. The committee made its recommendation following a review of 12-week safety data from patients enrolled in the trial as of June 30.

TRACON Pharmaceuticals says ENVASARC trial gets recommendation from review committee to proceed as planned

Review of Interim Efficacy Data by IDMC to Occur in Fourth Quarter Review of Interim Efficacy Data by IDMC to Occur in Fourth Quarter

TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from ENVASARC Phase 2 Pivotal Trial - Trial to Proceed as Planned

Lazydays

Protara Therapeutics Inc

Mountain Crest Acquisition Corp II

L. B. Foster

LINKBANCORP Inc

Liquidia Technologies Inc

Larimar Therapeutics Inc

Macerich

MFA Financial

B. Riley Financial

TransCode Therapeutics

Tilly's

Zivo Bioscience

In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.

News for TRACON Pharmaceuticals Stock (TCON)